Shopping Cart

Your shopping cart is currently empty

Ursodeoxycholic acid

Name: Ursodeoxycholic acid
Brand: TargetMol
SKU: T0700
Price: 29 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T0700Cas No. 128-13-2

Alias Ursodiol, UDCA

Ursodeoxycholic acid (UDCA) is a potent inhibitor of liver-specific fatty acid transporter 5 (FATP5). Ursodeoxycholic acid inhibits cholesterol absorption and is used to dissolve gallstones.

Ursodeoxycholic acid

Copy Product Info

😃Good

Purity: 99.91%

Catalog No. T0700Alias Ursodiol, UDCACas No. 128-13-2

Ursodeoxycholic acid (UDCA) is a potent inhibitor of liver-specific fatty acid transporter 5 (FATP5). Ursodeoxycholic acid inhibits cholesterol absorption and is used to dissolve gallstones.

Pack Size	Price	USA Warehouse	Global Warehouse
5 g	$42	-	In Stock
10 g	$59	-	In Stock
1 mL x 10 mM (in DMSO)	$29	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.91%

Appearance:Solid

Color:White

Resource Download

COA LCMS

Product Introduction

Ursodeoxycholic acid AI Summary

Ursodeoxycholic acid is a multifaceted chemical with a wide spectrum of bioactivities and evaluated physico-chemical properties. It demonstrates a high binding constant of 173,400.0 Kb M-1 towards a cyclodextrin conjugated peptide with pyrene at 25°C and exhibits a sensitivity change of 0.4 at this temperature. Its critical micellar concentration (CMC) is reported to be 19.0 mM, with a pKa value of 5.08 and water solubility at 9000.0 nM. The compound shows a Percent Hepatic Uptake of 50.0%, an Albumin Affinity Constant of 38,000.0 L M-1, and significant effects on bile flow and secretion of bile acids, cholesterol, and phospholipids in bile fistula rats. It activates the human PXR receptor, displays agonist activity at the human TGR5 receptor, and shows significant interactions with the human GPBAR1 and various nuclear receptors. Ursodeoxycholic acid has moderate lipophilicity (LogP = 4.014) and demonstrates varied effects on liver enzymes, with moderate hepatotoxicity observed in clinical trials. It inhibits glucuronosyltransferase activity in human colon cancer cells (HT-29) and shows potent inhibitory effects on several human tumor cell lines and Plasmodium falciparum M1-Family Alanyl Aminopeptidase. It modulates bile salt export pump (BSEP) and Taurocholate transport, and exhibits hepatoprotective activity in mice on a lithogenic diet, reducing gallstone formation and serum cholesterol levels. The compound shows modest antiviral activity against SARS-CoV-2, with some inhibition of the virus's 3CL-Pro protease and induced cytotoxicity in various cell lines. It has also exhibited antifungal activity against Candida albicans and Cryptococcus neoformans and antibacterial properties against several bacterial strains including Escherichia coli and Staphylococcus aureus MRSA. Despite the diverse bioactivity profile, Ursodeoxycholic acid does not induce significant drug-induced liver injury, has no cytotoxic impact against human HepG2 and Hep3B cells at low concentrations, and shows a varied efficacy when tested for anticancer activities on numerous human cell lines. Overall, Ursodeoxycholic acid demonstrates potential therapeutic applications across a broad range of biological targets and disease models, underscoring its significance in pharmaceutical research..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Ursodeoxycholic acid (UDCA) is a potent inhibitor of liver-specific fatty acid transporter 5 (FATP5). Ursodeoxycholic acid inhibits cholesterol absorption and is used to dissolve gallstones.
Targets&IC50	GBM:> 50 μM, CHO cells:36.4 μM (EC50), A549 cells:> 200 μM
In vitro	METHODS: Ovarian cancer cell line A2780 and cisplatin-resistant cell line A2780 were treated with Ursodeoxycholic acid (300 nM) for 4 hours, and the cell growth inhibition was detected by MTT assay. RESULTS: Ursodeoxycholic acid inhibited the growth of ovarian cancer A2780 cells (IC50=300 nM) and cisplatin-resistant A2780 cells (IC50=300 nM). [1] METHODS: Colorectal cancer cells SW620 and HCT116 were treated with Ursodeoxycholic acid (0, 0.00625, 0.0125, 0.025, 0.05, 0.1 mg/mL) for 24 hours, and MTT assay was used to detect the inhibitory effect of ursodeoxycholic acid on cell growth. RESULTS: Ursodeoxycholic acid inhibited the growth of colorectal cancer cells SW620 (IC50=0.02 mg/mL) and HCT116 (IC50=0.016 mg/mL). [2]
In vivo	METHODS: To study the effect of Ursodeoxycholic acid on body weight, Ursodeoxycholic acid (50, 150, and 450 mg/kg) was administered orally to mice for 21 days. RESULTS: Significant weight loss was observed within a week in the groups of mice receiving 50 and 450 mg/kg doses. At the 50 mg/kg dose, this weight loss persisted throughout the experiment. At a dose of 450 mg/kg, weight loss was initially observed during the first and third weeks of Ursodeoxycholic acid administration. At the 150 mg/kg dose, there was no significant difference in body weight compared to untreated mice. [3]
Synonyms	Ursodiol, UDCA

Chemical Properties

Molecular Weight	392.57
Formula	C₂₄H₄₀O₄
Cas No.	128-13-2
Smiles	C[C@@]12[C@]([C@]3([C@@]([C@]4(C)[C@](C[C@@H]3O)(C[C@H](O)CC4)[H])(CC1)[H])[H])(CC[C@@]2([C@@H](CCC(O)=O)C)[H])[H]
Relative Density.	1.128 g/cm3.

Storage & Solubility Information

Storage

keep away from moisture | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

Ethanol: 73 mg/mL (185.95 mM), Sonication is recommended.

DMSO: 255 mg/mL (649.57 mM), Sonication is recommended.

H2O: < 1 mg/mL (insoluble or slightly soluble)

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (12.74 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

Ethanol/DMSO

	1mg	5mg	10mg	50mg
1 mM	2.5473 mL	12.7366 mL	25.4732 mL	127.3658 mL
5 mM	0.5095 mL	2.5473 mL	5.0946 mL	25.4732 mL
10 mM	0.2547 mL	1.2737 mL	2.5473 mL	12.7366 mL
20 mM	0.1274 mL	0.6368 mL	1.2737 mL	6.3683 mL
50 mM	0.0509 mL	0.2547 mL	0.5095 mL	2.5473 mL
100 mM	0.0255 mL	0.1274 mL	0.2547 mL	1.2737 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc